Patents by Inventor Ken-ichi Fujimura
Ken-ichi Fujimura has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 7410987Abstract: A method of treating pain or pruritis comprising administering to a patient in need thereof a pharmaceutically effective amount of a ? opioid receptor agonist of the formula wherein R is an alkyl having an amino group as a substituent; and R1 is acyl.Type: GrantFiled: May 15, 2006Date of Patent: August 12, 2008Assignee: Santen Pharmaceutical Co., Ltd.Inventors: Maki Tokai, Takahiro Honda, Masashi Niwa, Yaeko Osumi, Ken-ichi Fujimura, Shin-ichi Kohno
-
Patent number: 7112598Abstract: A compound or a salt thereof having the following formula wherein R1 is acyl, R2 is hydrogen, halogen, unsubstituted alkyl or alkyl substituted by halogen; R3 is halogen or alkoxy; R4 is cycloalkyl, unsubstituted alkyl or alkyl substituted by cycloalkyl, aryl or hydroxyl or an ester thereof or alkoxy; R5 is hydroxyl or an ester thereof, alkoxy or alkoxyalkyl; or R4 and R5 are bonded with each other to form a pyrrolidine ring substituted by hydroxyl or an ester thereof, alkoxy or alkoxyalkyl; R6 is hydroxyl or an ester thereof, alkoxy, alkoxyalkoxy, alkoxyalkoxyalkoxy, mercapto or alkylthio; and A1 and A2, are the same or different, and are alkylene, provided that (i) when R4 and R5 are bonded to each other to form the pyrrolidine ring substituted by hydroxyl or an ester thereof, R2 is halogen; (ii) when R4 and R5 are bonded to each other to form the pyrrolidine ring substituted by alkoxyalkyl, R2 is hydrogen; (iii) when R6 is hydroxyl or an ester thereof, R4 is isopropyl.Type: GrantFiled: March 28, 2003Date of Patent: September 26, 2006Assignee: Santen Pharmaceutical Co., Ltd.Inventors: Maki Tokai, Takahiro Honda, Masashi Niwa, Yaeko Osumi, Ken-ichi Fujimura, Shin-ichi Kohno
-
Publication number: 20060205796Abstract: A method of treating pain or pruritis comprising administering to a patient in need thereof a pharmaceutically effective amount of a ? opioid receptor agonist of the formula wherein R is an alkyl having an amino group as a substituent; and R1 is acyl.Type: ApplicationFiled: May 15, 2006Publication date: September 14, 2006Applicant: SANTEN PHARMACEUTICAL CO., LTD.Inventors: Maki Tokai, Takahiro Honda, Masashi Niwa, Yaeko Osumi, Ken-ichi Fujimura, Shin-ichi kohno
-
Patent number: 6960575Abstract: A compound having 3-oxo-3, 4-dihydro-2H-1, 4-thiazine 4-tetrahydropyrazine as a main skeleton. The compound is a chymase inhibitor and is represented by the following formula [I] and salts thereof: In the formula [I], X is S; R1 and R2 are H, alkyl, cycloalkyl or aryl; R3 and R4 are H, alkyl, cycloalkyl, aryl or an aromatic heterocycle; R5 is H, alkyl, cycloalkyl, aryl or -A3-A4-R7; R6 is H, alkyl, cycloalkyl, hydroxy, alkoxy, aryl, aryloxy or an aromatic heterocycle; R7 is H, alkyl, hydroxy, alkoxy, aryl, aryloxy, amino, alkylamino, arylamino, an aromatic heterocycle or a nonaromatic heterocycle; A1 is alkylene; A2 is carbonyl or sulfonyl; A3 is alkylene; A4 is carbonyl or oxalyl; and n is 0 or 1.Type: GrantFiled: November 13, 2003Date of Patent: November 1, 2005Assignee: Santen Pharmaceutical Co., Ltd.Inventors: Kazuo Nishimura, Masakazu Ban, Ken-ichi Fujimura, Naoyuki Kobayashi, Masanori Hori, Takahiro Honda, Eiko Matsumoto, Junzo Matsumoto
-
Publication number: 20050113430Abstract: The present invention provides ? opioid receptor agonists comprising 2-phenylbenzothiazoline derivatives. The present invention relates to ? opioid receptor agonists comprising compounds or salts thereof having the chemical structure represented by the general formula [I]. Namely, it is important for exhibition of the ? opioid receptor agonist actions to have an alkyl group having an amino group at a phenyl group of 2-phenylbenzothiazoline as a substituent and to have an acyl group at a nitrogen atom of 2-phenylbenzothiazoline, wherein R is alkyl having the amino group as the substituent; and R1 is acyl.Type: ApplicationFiled: March 28, 2003Publication date: May 26, 2005Applicant: Santen Pharmaceutical Co., LTDInventors: Maki Tokai, Takahiro Honda, Yaeko Osumi, Ken-ichi Fujimura
-
Publication number: 20040097496Abstract: A compound having 3-oxo-3,4-dihydro-2H-1,4-thiazine 4-tetrahydropyrazine as a main skeleton.Type: ApplicationFiled: November 13, 2003Publication date: May 20, 2004Applicant: SANTEN PHARMACEUTICAL CO.,LTD.Inventors: Kazuo Nishimura, Masakazu Ban, Ken-Ichi Fujimura, Naoyuki Kobayashi, Masanori Hori, Takahiro Honda, Junzo Matsumoto, Eiko Matsumoto
-
Patent number: 6713472Abstract: A compound which is a chymase inhibitor and which is represented by a formula [I] and salts thereof. In the formula [I], X is R6—(A2)n—N, R1 and R2 are H, alkyl, cycloalkyl or aryl, R3 and R4 are H, alkyl, cycloalkyl, aryl or aromatic heterocycle, R5 is H, alkyl, cycloalkyl, aryl or —A3—A4—R7, R6 is H, alkyl, cycloalkyl, OH, alkoxy, aryl, aryloxy or an aromatic heterocycle, R7 is H, alkyl, OH, alkoxy, aryl, aryloxy, amino, alkylamino, arylamino, an aromatic heterocycle or a nonaromatic heterocycle, A1 is alkylene, A2 is carbonyl or sulfonyl, A3 is alkylene, A4 is carbonyl or oxalyl and n is o or 1.Type: GrantFiled: January 18, 2002Date of Patent: March 30, 2004Assignee: Santen Pharmaceutical Co., Ltd.Inventors: Kazuo Nishimura, Masakazu Ban, Ken-ichi Fujimura, Naoyuki Kobayashi, Masanori Hori, Eiko Matsumoto
-
Patent number: 6410576Abstract: An object of the present invention is to provide novel thiazolidine derivatives which are useful as drugs. The thiazolidine derivatives according to the present invention are compounds represented by the following general formula [I] and salts thereof, wherein R1 is alkyl, hydroxy, alkoxy, alkoxyalkyl, phenyl, phenylalkyl, phenylalkoxy, phenoxy, phenoxyalkyl, amino, alkylamino or a nonaromatic heterocycle; R2 is H or alkyl; R3 is H, alkyl or phenyl; R4 is H or alkyl; R5 is alkyl, halogenoalkyl, hydroxy, alkoxy, phenyl, phenylalkoxy, phenoxy, carboxyl, alkoxycarbonyl, phenylalkoxycarbonyl or an aromatic heterocycle; A1 is alkylene; and A2 is alkylene.Type: GrantFiled: January 29, 2001Date of Patent: June 25, 2002Assignee: Santen Pharmaceutical Co., Ltd.Inventors: Kazuo Nishimura, Ken-ichi Fujimura, Junzo Matsumoto, Tadayuki Kobayashi
-
Patent number: 6242476Abstract: The present invention relates to leukotriene A4 hydrolase inhibitors containing compounds represented by the formula [I] or salts thereof as active ingredients, wherein R1 represents hydrogen, alkyl, phenylalkyl, alkanoyl or benzoyl; R2 and R3 each represent hydrogen or alkyl; R4 represents hydroxyl, alkoxy, phenylalkoxy, amino, alkylamino or phenylalkylamino; R5 represents phenylalkyl or naphthylalkyl; “Z” represents sulfur or oxygen; “A” represents alkylene; and “n” represents 0, 1 or 2; providing that the phenyl ring in R1 can be substituted by alkyl, alkoxy or halogen, and that the phenyl ring or the naphthyl ring in R5 can be substituted by alkyl, cycloalkyl, alkoxy, alkylthio or halogen.Type: GrantFiled: September 17, 1999Date of Patent: June 5, 2001Assignee: Santen Pharmaceutical Co., Ltd.Inventors: Shiro Mita, Masato Horiuchi, Masakazu Ban, Ken-ichi Fujimura, Hiroshi Suhara
-
Patent number: 5968980Abstract: The present invention relates to compounds represented by the formula [I] and salts thereof, wherein R.sup.1 and R.sup.5 each represents carboxyl, phosphonic or a derivative thereof; R.sup.2 represents hydrogen, lower alkyl, (substituted) phenyl lower alkyl, lower alkoxy or (substituted) phenyl lower alkoxy; R.sup.3 represents lower alkyl or (substituted) phenyl lower alkyl; and R.sup.4 represents a group represented by the formula [XI], [XII] or [XIII]. The compounds of the present invention have endopeptidase 24.11 inhibitory activity and are useful for treating cardiovascular diseases such as heart failure and hypertension, renal diseases such as renal failure, gastroenteric disorders such as diarrhea and hyperchlorhydria, endocrine and metabolic diseases such as obesity, and autoimmune diseases such as rheumatic disease, and for mitigating myosalgia, migraine, etc.Type: GrantFiled: June 3, 1997Date of Patent: October 19, 1999Assignee: Santen Pharmaceutical Co., Ltd.Inventors: Yoichi Kawashima, Ken-ichi Fujimura, Hiroshi Suhara, Noriyoshi Yamamoto, Hiromi Matsumoto, Nobuaki Miyawaki, Yuko Fujita
-
Patent number: 5891912Abstract: The present invention related to compounds represented by the following formula (I) and salts thereof, ##STR1## wherein R.sup.1 and R.sup.4 each represents a carboxyl or a carboxyl which is converted into an ester, an amide or hydroxamic acid; R.sup.2 represents a lower alkyl or a phenyl-lower alkyl; R.sup.3 represents a hydrogen atom, a lower alkyl, an amino-lower alkyl, a lower alkylamino-lower alkyl, a hydroxy-lower alkyl, a mercapto-lower alkyl, a carboxy-lower alkyl, a lower alkoxycarbonyl-lower alkyl, an imidazolyl-lower alkyl, an indolyl-lower alkyl, a (substituted) phenyl group, a (substituted) phenyl-lower alkyl group, a (substituted) naphthyl group, or a (substituted) naphtyl-lower group. The compounds of the present invention have inhibitory effects on endopeptidase 24.Type: GrantFiled: July 15, 1996Date of Patent: April 6, 1999Assignee: Santen Pharmaceutical Co., Ltd.Inventors: Yoichi Kawashima, Ken-ichi Fujimura, Hiroshi Suhara, Nobuaki Miyawaki, Yuko Fujita
-
Patent number: 5350860Abstract: A compound of the formula [I]. ##STR1## The compounds of this invention has excellent thymulin-line activities and expected to be useful for treatment of various diseases such as immunodeficiency and autoimmune diseases.Type: GrantFiled: January 19, 1993Date of Patent: September 27, 1994Assignee: Santen Pharmaceutical Co., Ltd.Inventors: Shiro Mita, Yoichi Kawashima, Ken-ichi Fujimura, Hiroshi Suhara, Masahiro Okamoto